Inabe-gun, Japan

Shoji Yokochi

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 9.3

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Nagoya, JP (1999)
  • Inabe-gun, JP (2003 - 2007)
  • Tokyo, JP (2020 - 2024)

Company Filing History:


Years Active: 1999-2024

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Shoji Yokochi

Introduction

Shoji Yokochi is a prominent inventor based in Inabe-gun, Japan. He has made significant contributions to the field of cancer therapy, holding a total of 12 patents. His work focuses on developing novel therapeutic means that are effective and practical against cancer.

Latest Patents

One of Yokochi's latest patents involves HMGN partial peptides and their application in cancer therapy. This patent discloses a novel therapeutic means that includes peptides derived from a partial region of HMGN1, HMGN2, HMGN4, or HMGN5. These peptides serve as anti-cancer agents and effect enhancers, demonstrating an independent anti-tumor effect. Furthermore, they exhibit a remarkably excellent anti-tumor effect when used in combination with immune checkpoint regulators or anti-CD4 antibodies.

Career Highlights

Throughout his career, Shoji Yokochi has worked with notable companies such as Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd. His experience in these organizations has contributed to his expertise in the field of cancer research and therapy.

Collaborations

Yokochi has collaborated with esteemed colleagues, including Yoshiro Ishiwata and Kouji Matsushima. These partnerships have further enhanced his research and development efforts in innovative cancer treatments.

Conclusion

Shoji Yokochi's contributions to cancer therapy through his innovative patents and collaborations highlight his significant role in advancing medical science. His work continues to inspire future research in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…